Welcome to the Razadyne ER web site.
In order to view this web site correctly you will need to upgrade your version of Flash Player.
There have been reports of name confusion between RAZADYNE®, our treatment for the symptoms of mild to moderate Alzheimer’s disease and ROZEREM®, a medication for the treatment of insomnia, marketed by Takeda Pharmaceuticals America, Inc. Click here to learn more.
RAZADYNE® ER is used to treat the symptoms of mild to moderate Alzheimer's disease such as memory loss.
There is no evidence that galantamine alters the course of the underlying dementing process.
IMPORTANT SAFETY INFORMATION
RAZADYNE® ER is not for everyone, including people who are allergic to any ingredients in RAZADYNE® ER.
Some people experience a slowed heart rate, which may lead to fainting. Call your doctor right away if a patient faints while taking RAZADYNE® ER.
Serious stomach problems, including bleeding, can occur in people taking medications such as non-steroidal anti-inflammatory drugs (NSAIDs) or those at risk for stomach problems. Tell your doctor about all of the medications you are taking including NSAIDs or aspirin.
People may have seizures while taking RAZADYNE® ER. People may also have problems passing urine and people with lung problems such as severe asthma may worsen. Call your doctor if any of these occur.
In clinical trials, once-daily treatment with RAZADYNE® ER was well tolerated and the adverse events were similar to those seen with twice daily RAZADYNE® tablets.
The most common adverse events occurring with the recommended maintenance dose of either 16 or 24 mg/day were nausea, vomiting, diarrhea, anorexia, and weight decrease.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
For more information, read the full US Prescribing Information by clicking here.
ROZEREM® is a registered trademark of Takeda Pharmaceutical and used under license by Takeda Pharmaceuticals America, Inc.
Privacy Policy | Full Prescribing Information | Legal Notice | Contact Us | Janssen Pharmaceuticals, Inc.
This page was last updated on: May 14 2012 at 12:25:45 EDT